Response to radiation

K. E. Rosenzweig; J. L. Fox; P. Giraud

doi:10.1016/j.semradonc.2004.06.002

Response to radiation

K. E. Rosenzweig, J. L. Fox, P. Giraud

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Computed tomography (CT) has traditionally been the standard radiographic modality for diagnosing and monitoring non-small cell; lung cancer (NSCLC) after treatment. Given the limitations of CT, the utility of ¹⁸F-fluoro-2- deoxy-glucose positron emission tomography (FDG-PET) has been investigated for the management of NSCLC, with promising findings. Its adjunctive role with CT in diagnosing and staging disease is well established. FDG-PET also has been found to be a valuable tool for radiation treatment planning because it improves the precision of lesion definition. More recently, its value for determining clinical response both during and after treatment has been explored. This review highlights the various applications of FDG-PET in the diagnosis and management of NSCLC as corroborated by clinical data, with considerations of future directions.

Original language	English (US)
Pages (from-to)	322-325
Number of pages	4
Journal	Seminars in Radiation Oncology
Volume	14
Issue number	4
DOIs	https://doi.org/10.1016/j.semradonc.2004.06.002
State	Published - Oct 2004
Externally published	Yes

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.semradonc.2004.06.002

Cite this

@article{f19f92bc1d804fe69038918740ee7471,

title = "Response to radiation",

abstract = "Computed tomography (CT) has traditionally been the standard radiographic modality for diagnosing and monitoring non-small cell; lung cancer (NSCLC) after treatment. Given the limitations of CT, the utility of 18F-fluoro-2- deoxy-glucose positron emission tomography (FDG-PET) has been investigated for the management of NSCLC, with promising findings. Its adjunctive role with CT in diagnosing and staging disease is well established. FDG-PET also has been found to be a valuable tool for radiation treatment planning because it improves the precision of lesion definition. More recently, its value for determining clinical response both during and after treatment has been explored. This review highlights the various applications of FDG-PET in the diagnosis and management of NSCLC as corroborated by clinical data, with considerations of future directions.",

author = "Rosenzweig, {K. E.} and Fox, {J. L.} and P. Giraud",

year = "2004",

month = oct,

doi = "10.1016/j.semradonc.2004.06.002",

language = "English (US)",

volume = "14",

pages = "322--325",

journal = "Seminars in Radiation Oncology",

issn = "1053-4296",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Response to radiation

AU - Rosenzweig, K. E.

AU - Fox, J. L.

AU - Giraud, P.

PY - 2004/10

Y1 - 2004/10

N2 - Computed tomography (CT) has traditionally been the standard radiographic modality for diagnosing and monitoring non-small cell; lung cancer (NSCLC) after treatment. Given the limitations of CT, the utility of 18F-fluoro-2- deoxy-glucose positron emission tomography (FDG-PET) has been investigated for the management of NSCLC, with promising findings. Its adjunctive role with CT in diagnosing and staging disease is well established. FDG-PET also has been found to be a valuable tool for radiation treatment planning because it improves the precision of lesion definition. More recently, its value for determining clinical response both during and after treatment has been explored. This review highlights the various applications of FDG-PET in the diagnosis and management of NSCLC as corroborated by clinical data, with considerations of future directions.

AB - Computed tomography (CT) has traditionally been the standard radiographic modality for diagnosing and monitoring non-small cell; lung cancer (NSCLC) after treatment. Given the limitations of CT, the utility of 18F-fluoro-2- deoxy-glucose positron emission tomography (FDG-PET) has been investigated for the management of NSCLC, with promising findings. Its adjunctive role with CT in diagnosing and staging disease is well established. FDG-PET also has been found to be a valuable tool for radiation treatment planning because it improves the precision of lesion definition. More recently, its value for determining clinical response both during and after treatment has been explored. This review highlights the various applications of FDG-PET in the diagnosis and management of NSCLC as corroborated by clinical data, with considerations of future directions.

UR - http://www.scopus.com/inward/record.url?scp=8844223434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844223434&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2004.06.002

DO - 10.1016/j.semradonc.2004.06.002

M3 - Article

C2 - 15558507

AN - SCOPUS:8844223434

SN - 1053-4296

VL - 14

SP - 322

EP - 325

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

IS - 4

ER -

Response to radiation

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this